Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$103.89 USD

103.89
639,197

+0.93 (0.90%)

Updated Aug 8, 2025 10:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Urmimala Biswas headshot

MedTech Stocks' Q1 Earnings on Apr 25: BSX, TMO and More

by Urmimala Biswas

MedTech companies' results are likely to reflect a sequential decline. Let's see how BSX, TMO, EW and ALGN fare this time.

Zacks Equity Research

Here's Why You Should Buy Boston Scientific (BSX) Stock

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) owing to impressive growth in MedSurg market share.

Zacks Equity Research

What's in Store for Boston Scientific (BSX) in Q1 Earnings?

by Zacks Equity Research

Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies in the first quarter.

Zacks Equity Research

The Zacks Analyst Blog Highlights Eli Lilly, Thermo Fisher Scientific, Lockheed Martin, Boston Scientific and Canadian Pacific Railway

by Zacks Equity Research

Eli Lilly, Thermo Fisher Scientific, Lockheed Martin, Boston Scientific and Canadian Pacific Railway are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for Eli Lilly, Thermo Fisher Scientific & Lockheed Martin

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Thermo Fisher Scientific Inc. (TMO) and Lockheed Martin Corporation (LMT).

Zacks Equity Research

Boston Scientific (BSX) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Boston Scientific (BSX) outperforms the industry and the S&P 500 due to several new acquisitions and the long-term growth prospects of the WATCHMAN device.

Zacks Equity Research

VREX or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

VREX vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Retain Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX), led by impressive value-added acquisitions.

Zacks Equity Research

Abbott (ABT) Makes Progress in the TAVI Space With Navitor

by Zacks Equity Research

Results from Abbott's (ABT) PORTICO study support Navitor's recent FDA approval to treat patients with severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Zacks Equity Research

Abbott's (ABT) MitraClip Device Shows Favorable Outcome

by Zacks Equity Research

Abbott's (ABT) landmark COAPT trial demonstrated that MitraClip is safe and effective and can reduce the hospitalization rate.

Zacks Equity Research

Boston Scientific (BSX) Down 1.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

Boston Scientific (BSX) Gains From New Buyouts, Cost Woes Stay

by Zacks Equity Research

Boston Scientific's (BSX) EMEA business grows above market, supported by the company's ongoing investments in emerging markets.

Zacks Equity Research

Boston Scientific (BSX) Q4 Earnings Miss, Operating Margin Up

by Zacks Equity Research

Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in the fourth quarter of 2022.

Zacks Equity Research

Boston Scientific (BSX) Lags Q4 Earnings Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of -4.26% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Device Stocks' Earnings on Feb 1: BSX, TMO & More

by Urmimala Biswas

Medical device companies' results are likely to reflect a sequential decline. Let's see how BSX, TMO, HOLX and ALGN fare this time.

Zacks Equity Research

Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline

by Zacks Equity Research

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Retain Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on recent acquisitions and robust performance of the WATCHMAN device.

Zacks Equity Research

Will Boston Scientific (BSX) Beat Q4 Earnings Estimates?

by Zacks Equity Research

Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies.

Zacks Equity Research

Charles River (CRL) to Develop RNA-based Therapy With New Pact

by Zacks Equity Research

Charles River's (CRL) new partnership will enable the clinical development of RNA-based anticancer gene therapy in liver cancer patients.

Zacks Equity Research

IDEXX (IDXX) Aided by Global Growth, Solid Instrument Placement

by Zacks Equity Research

IDEXX's (IDXX) rapid assay revenue growth is supported by solid volume gains in the United States and benefits from net price increases.

Zacks Equity Research

Charles River (CRL) to Advance DNA Programs With New Launch

by Zacks Equity Research

Charles River's (CRL) launch of the eXpDNA plasmid manufacturing platform is intended to support vaccine and advanced therapy clients through clinical trials and beyond.

Zacks Equity Research

NuVasive (NUVA) Suffers From Macro Headwinds, Price Issue

by Zacks Equity Research

NuVasive (NUVA) believes that its 2022 guidance is appropriately conservative, considering macroeconomic pressures on net sales and operating profit.

Zacks Equity Research

QIAGEN (QGEN) Gains From Innovation, Currency Headwind Ails

by Zacks Equity Research

The QuantiFERON franchise is a key driver behind QIAGEN's (QGEN) molecular diagnostics growth.